Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,851.50    31.00 (1.70%)
Bid:
1,851.50
Ask:
1,852.00
Spread: 0.50 (0.027%)
Market Cap: £74.25b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Director/PDMR Shareholding

15 Feb 2023 16:00

RNS Number : 0539Q
GSK PLC
15 February 2023
 

GSK plc (the 'Company')

Vesting of Conditional Share Awards under the Share Value Plan and Sale of Ordinary Shares and American Depositary Shares

This notification sets out the vesting details for Person Discharging Managerial Responsibilities ('PDMRs') of Conditional Share Awards over Ordinary Shares and American Depositary Shares ('ADSs') made in 2020 under the GlaxoSmithKline Share Value Plan and the subsequent sale of Ordinary Shares and ADSs to meet tax liabilities. The awards, which were conditional on continued employment with the GSK group, vested on 14 February 2023. 

 

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Jackson

b)

Position/status

PCA of Ms S Jackson (SVP, Global Communications and CEO Office)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The vesting of Ordinary Shares awarded in 2020 under the Company's Share Value Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

6,330

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

e)

Date of the transaction

2023-02-14

f)

Place of the transaction

 

N/A

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Jackson

b)

Position/status

PCA of Ms S Jackson (SVP, Global Communications and CEO Office)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2020 under the Company's Share Value Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.7819

.

2,976

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

e)

Date of the transaction

2023-02-14

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

  

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms S Ramakrishnan

b)

Position/status

Chief Digital and Technology Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W2044

b)

Nature of the transaction

The vesting of ADSs awarded in 2020 under the Company's Share Value Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$0.00

.

5,740

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

e)

Date of the transaction

2023-02-14

f)

Place of the transaction

 

N/A

   

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms S Ramakrishnan

b)

Position/status

Chief Digital and Technology Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W2044

b)

Nature of the transaction

The sale of ADSs to meet tax liabilities on the vesting of awards granted in 2020 under the Company's Share Value Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$35.9588

.

3,063

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

e)

Date of the transaction

2023-02-14

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

  

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr T Wood

b)

Position/status

Chief Scientific Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The vesting of Ordinary Shares awarded in 2020 under the Company's Share Value Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

8,314

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

e)

Date of the transaction

2023-02-14

f)

Place of the transaction

 

N/A

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr T Wood

b)

Position/status

Chief Scientific Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2020 under the Company's Share Value Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.7819

.

3,908

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

e)

Date of the transaction

2023-02-14

f)

Place of the transaction

 

London Stock Exchange (XLON)

   

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms V Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The vesting of Ordinary Shares awarded in 2020 under the Company's Share Value Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

10,050

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

e)

Date of the transaction

2023-02-14

f)

Place of the transaction

 

N/A

   

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms V Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2020 under the Company's Share Value Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.7819

.

4,724

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

e)

Date of the transaction

2023-02-14

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSFFFLIEDSEIE
Date   Source Headline
20th Aug 20247:00 amRNSB7-H3 ADC US FDA Breakthrough Therapy Designation
16th Aug 20247:00 amRNSStatement: Zantac (ranitidine) litigation
12th Aug 20243:30 pmRNSDirector/PDMR Shareholding
6th Aug 20247:00 amRNSStatement: Zantac (ranitidine) litigation
2nd Aug 20247:00 amRNSFDA Expands Jemperli Approval
1st Aug 20243:00 pmRNSTotal Voting Rights
31st Jul 20247:00 amRNS2nd Quarter Results
29th Jul 20248:18 amRNSStatement: Zantac (ranitidine) litigation
29th Jul 20247:00 amRNSCHMP positive opinion on Arexvy for 50-59 at risk
19th Jul 202410:36 amRNSBlenrep EMA Filing Acceptance
18th Jul 20243:30 pmRNSDirector/PDMR Shareholding
16th Jul 20243:30 pmRNSDirector/PDMR Shareholding
15th Jul 20243:30 pmRNSDirector/PDMR Shareholding
12th Jul 20243:30 pmRNSDirector/PDMR Shareholding
3rd Jul 20247:00 amRNSGSK and CureVac collaboration restructured
1st Jul 20243:00 pmRNSTotal Voting Rights
28th Jun 20245:37 pmRNSStatement: Zantac (ranitidine) litigation
24th Jun 20247:05 amRNSOmjjara approved in Japan for myelofibrosis
24th Jun 20247:00 amRNSEMA validates Jemperli marketing authorisation
21st Jun 20243:30 pmRNSDirector/PDMR Shareholding
12th Jun 20243:30 pmRNSDirector/PDMR Shareholding
11th Jun 20247:00 amRNSStatement: Zantac (ranitidine) litigation
10th Jun 20246:27 pmRNSStatement: Zantac (ranitidine) litigation
10th Jun 20247:00 amRNSFDA approves Arexvy for adults 50-59 at risk
3rd Jun 20243:00 pmRNSTotal Voting Rights
3rd Jun 20241:03 pmRNSUnprecedented results in Jemperli trial continue
3rd Jun 20247:05 amRNSASCO positive Blenrep DREAMM-8 trial results
3rd Jun 20247:00 amRNSStatement: Zantac (ranitidine) litigation
24th May 20247:00 amRNSStatement: Zantac (ranitidine) litigation
21st May 20247:00 amRNSPositive phase III asthma results for depemokimab
20th May 20243:30 pmRNSDirector/PDMR Shareholding
17th May 20247:00 amRNSGSK completes sale of shares in Haleon plc
16th May 20244:42 pmRNSGSK announces intention to sell shares in Haleon
14th May 20243:30 pmRNSDirector/PDMR Shareholding
13th May 20243:00 pmRNSBlock listing Interim Review
8th May 20246:21 pmRNSResult of AGM
8th May 20244:57 pmRNSBoard Committee Change
3rd May 20243:30 pmRNSDirector/PDMR Shareholding
1st May 20243:00 pmRNSTotal Voting Rights
1st May 20247:00 amRNS1st Quarter Results
24th Apr 20247:00 amRNSUS FDA accepts new indication filing for Jemperli
19th Apr 20243:30 pmRNSDirector/PDMR Shareholding
17th Apr 20243:30 pmRNSDirector/PDMR Shareholding
17th Apr 20247:05 amRNSGSK announces additional EAGLE-1 results
17th Apr 20247:00 amRNSResults from long-term data relating to Shingrix
16th Apr 20242:11 pmRNSAmendment - Director/PDMR Shareholding
16th Apr 20247:00 amRNSFDA accepts GSK meningitis vaccine candidate file
15th Apr 20243:30 pmRNSDirector/PDMR Shareholding
4th Apr 202412:05 pmRNSReplacement - Total Voting Rights
2nd Apr 20243:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.